About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Our team
Portfolio
News
Connect
Pages
Pages
Home
About
Blog
Blog Post
Contact
Portfolio
Investors
Investor Single
Shop
Shop Single
Utility Pages
Start Here
Style Guide
404 Not Found
Password Protected
Licenses
Changelog
Browse More Templates
Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors
Article Date
October 28, 2025
This article is featured on another website.
Go to article
Related posts
Browse all articles
April 20, 2026
Advancing Cross‑Border Clinical Development: HiRO at BIO Korea 2026
HiRO to Attend BIO Korea 2026, April 28–30 in Seoul HiRO is excited to announce…
April 20, 2026
Advancing Cross‑Border Clinical Development: HiRO at BIO Korea 2026
HiRO to Attend BIO Korea 2026, April 28–30 in Seoul HiRO is excited to announce…
April 9, 2026
Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
April 9, 2026
Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe